Mr. Riley has more than 25 years of leadership experience in the pharmaceutical and biotechnology industries. He has extensive business development and capital markets experience, including negotiating numerous worldwide strategic corporate alliances, establishing joint ventures, and assisting in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. Mr. Riley’s healthcare and biotechnology experience includes leadership positions with SmithKline Beecham, Pfizer, Quest Diagnostics, Xenome, Amphora and Ontogen and most recently as CEO, President and Director of Synthetic Biologics. Mr. Riley has served on numerous public and private Boards in the U.S., Europe and Australia.